Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Cell Culture, Engineering and Formulation Techniques

Tudor Arvinte's Biography



Tudor Arvinte, Chairman and CEO, Therapeomics Inc/University of Geneva

Tudor Arvinte, Ph.D., received his academic training in physics at the University of Jassy, Romania, and his Ph.D. in biophysics from the University of Düsseldorf, Germany. He performed his doctoral work and postdoctoral stage at the Max-Planck-Institute West Germany and held numerous research positions in Europe and the USA. In 1989 he joined Ciba-Geigy Pharmaceuticals in Horsham, England, and in 1994 he moved to Ciba-Geigy in Basel, Switzerland. Until 2002 he worked as Head of Exploratory Formulation, Novartis Biotechnology Development & Production, Basel. T. Arvinte worked on the characterization and formulation of about 80 protein and peptide drugs. T. Arvinte has over 80 publications and holds 13 patents on formulations of proteins. Since 2001 he is Invited Professor at the School of Pharmacy, University of Geneva. T. Arvinte is also Visiting Professor at the Department of Pharmacy, School of Health and Life Sciences King’s College London, UK. In 2003 T. Arvinte co-founded Therapeomic, Inc., a biotech company focused on developing formulations for biopharmaceuticals in collaborations with pharmaceutical companies.

Tudor Arvinte Image

The Importance of Formulation for the Proof of Concept and for the Success of Biopharmaceuticals

Wednesday, 20 July 2011 at 16:30

Add to Calendar ▼2011-07-20 16:30:002011-07-20 17:30:00Europe/LondonThe Importance of Formulation for the Proof of Concept and for the Success of BiopharmaceuticalsSELECTBIOenquiries@selectbiosciences.com

One possibility to increase the success rates of new biotech drugs is to improve the formulation. In early stages projects may die due to the use of not optimized protein formulations and the failure is falsely attributed to the molecule instead. The investment in a good proof-of-concept, enabling formulation, is minimal compared with the risk that companies are taking in performing human studies with non- optimized formulations.


Add to Calendar ▼2011-07-20 00:00:002011-07-21 00:00:00Europe/LondonCell Culture, Engineering and Formulation TechniquesSELECTBIOenquiries@selectbiosciences.com